TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04134728

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3196165 (Otilimab)
Description: GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3196165 (Otilimab)
Description: GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: GSK3196165 (Otilimab)
Description: GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: GSK3196165 (Otilimab)
Description: GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sarilumab
Description: Sarilumab solution in PFS to be administered SC.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sarilumab
Description: Sarilumab solution in PFS to be administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to GSK3196165/ Sarilumab
Description: Placebo sterile 0.9 percentage (%) weight by volume (w/v) sodium chloride solution in vial/PFS to be administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to GSK3196165/ Sarilumab
Description: Placebo sterile 0.9 percentage (%) weight by volume (w/v) sodium chloride solution in vial/PFS to be administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to GSK3196165/ Sarilumab
Description: Placebo sterile 0.9 percentage (%) weight by volume (w/v) sodium chloride solution in vial/PFS to be administered SC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to GSK3196165/ Sarilumab
Description: Placebo sterile 0.9 percentage (%) weight by volume (w/v) sodium chloride solution in vial/PFS to be administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: csDMARDs
Description: Stable dose of csDMARD(s) as SoC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: csDMARDs
Description: Stable dose of csDMARD(s) as SoC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: csDMARDs
Description: Stable dose of csDMARD(s) as SoC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: csDMARDs
Description: Stable dose of csDMARD(s) as SoC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: csDMARDs
Description: Stable dose of csDMARD(s) as SoC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: csDMARDs
Description: Stable dose of csDMARD(s) as SoC.
Study: NCT03905824

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic stromal mesenchymal cells derived from the umbilical cord
Description: Platelet-poor plasma (PPP) scaffold embedded in allogenic stromal mesenchymal cells derived from the umbilical cord added to the traditional treatment for osteochondral lesions of the talus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Debridement and microfracture
Description: Debridement and microfracture in LOC is the traditional treatment for osteochondral lesions of the talus

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Debridement and microfracture
Description: Debridement and microfracture in LOC is the traditional treatment for osteochondral lesions of the talus
Study: NCT00794755

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K1 (Phytonadione)
Description: Vitamin K1 tablets (100 micrograms per tablet) will be taken by patients randomized to the Vitamin K arm. Dosage is two tablets per day (200 micrograms per day) to be taken with warfarin for the 6 month study period.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose-based placebo tablets (identical in appearance to the Vitamin K1 tablets) will be taken by patients randomized to the placebo arm. Dosage is two tablets per day to be taken with warfarin for the 6 month study period.
Study: NCT02924636

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ePPOP-ID program
Description: This is a personalized and online program. The website will provide secure communication with dietician and lifestyle coaches.
Study: NCT03945201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual walking trails
Description: During time on the treadmill, participants walk in front of Bionautica Trails, the virtual walking trails created by Plas.md. Participants can select between seven trails including various nature themed trails and a space setting. While walking, participants wear wireless headphones that provide audio of cardiac rehabilitation education at random intervals. These education pieces cover six categories of information: Understanding Your Heart Condition, Diet, Exercise, Medication, Managing Risk Factors, and Emotional Health.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Participants receive normal standard of care cardiac rehabilitation, completing multiple pieces of exercise equipment at increasing intervals according to the Jefferson Methodist Cardiac Rehabilitation program's protocols. Participants are given the option to use the treadmill for up to 15 minutes.
Study: NCT02478918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone call
Description: Automated phone call reminder
Study: NCT04479449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-8203
Description: SP-8203 80 mg will be intravenously administered as 40 mg/dose twice daily (intervals of 12 hours)
Study: NCT02001831

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00006237

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: interferon alfa
Description: Given IV and subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: interferon alfa
Description: Given IV and subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine
Description: Given IV
Study: NCT02200562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab and dabrafenib
Study: NCT03409835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Description: Ramosetron 0.3 mg is administered after induction of general anesthesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline 2 ml is administered after induction of general anesthesia.
Study: NCT03641443

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive measurement of intracranial pressure
Description: Non-invasive measurement of intracranial pressure in patients with mass effective brain Tumors
Study: NCT06242158

Intervention type: PROCEDURE
Intervention: arthroscopic assisted mini-open 5 step repair
Description: First step Identifying the tear size , quality and if reducible on the foot print . minimal removal of the bursa and pulling of the tendon with a grasper to reach the foot print area with gentle mobilization of the tendon .~Step two Acromioplasty Using a probe, the LHBT was palpated and mobilized, looking for any signs of degeneration and fraying or instability . The LHBT was inspected either through the tear by the subacrominal portal or through the glenohumeral portal .~Step three Antero-lateral mini-open approach was used through a longitudinal 4 cm skin incision Step four Transosseous repair using the giant needle was used. 3 to 4 number two fiber wire sutures was passed equidistance through the tendon Step five The subarominal bursa was used for biological augmentation of the repair
Study: NCT03335098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Six 4-week cycles
Study: NCT01910025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20
Study: NCT02216591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Cognitive Training (ACT)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control (CON)
Study: NCT02615730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2636771
Description: Increasing dose levels of GSK2636771 (300 mg or 400 mg once daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: fixed dose of paclitaxel (80 mg/m2 on Days 1, 8 and 15 of a 28-day treatment cycle)
Study: NCT03366155

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Codman 3000 constant flow pump catheter
Description: implanted Medtronic SynchroMed II Pump with codman 3000 Constant Flow Pump Catheter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: 6 mg/kg, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FUDR-Dex
Description: HAIP will be filled with mixture of Floxuridine and Dexamethasone. Pump will perfuse drugs to liver for 14 days. Floxuridine (0.12 mg/kg X pump volume X pump flow rate),Dexamethasone (1 mg/day X pump volume (30) X pump flow rate)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU
Description: 2000 mg/m2, IV 46-hour infusion of 5-Fluorouracil + 400 mg/m2, IV of Leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 150 mg/m2, IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAIP installation
Description: HAI pump installation
Study: NCT04479449

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be intravenously administered twice daily (intervals of 12 hours)
Study: NCT03619837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Velpatasvir
Description: Sofosbuvir/Velpatasvir starting early post-transplant for total of 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Velpatasvir/Voxilaprevir
Description: Only for patients who fail initial treatment with Sofosbuvir/Velpatasvir.~Dosage: 400mg/100mg/100mg daily for 12 weeks.
Study: NCT00533169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474
Description: Part A = Starting dose 50 mg/m\^2 by mouth daily for 28 days; Part B, C = Starting dose 50 mg/m\^2 by mouth daily on days 2-28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retinoic Acid
Description: Part B, C = 80 mg/m\^2 by mouth twice daily for 2 consecutive weeks out of every four weeks (28 days).
Study: NCT03802240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI305
Description: 15mg/kg IV Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: 500mg/m2 IV Q3W
Study: NCT04575766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-7051
Description: Dose levels: Dose Level -1 through Dose Level 7, assigned per the protocol using a BOIN design. Additional dose levels may be explored as applicable.~Capsules available in strengths of 10mg, 25mg, and 100 mg that are orally administered per the protocol frequency and dose level.
Study: NCT00527306

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: multivitamin
Description: Subject will be asked to take a multivitamin capsule or a placebo (inactive pill) once a day for one year. There will be an equal chance of getting the multivitamin or the placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: multivitamin
Description: Subject will be asked to take a multivitamin capsule or a placebo (inactive pill) once a day for one year. There will be an equal chance of getting the multivitamin or the placebo.
Study: NCT00106067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: coping and communication support (CCS) intervention
Description: Trained clinical nurse specialists with masters� degrees in mental health will serve as CCS practitioners and they will be available to patients and family caregivers on a 24/7 basis to assist with coping and communication challenges as they may arise.~The CCS intervention is tailored to individual preferences over time, and designed to accommodate different age groups, especially older adults and their families.
Study: NCT03760003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464 25mg
Description: ABX464 25mg (One capsule of ABX464 25 mg + One capsule of placebo) once daily for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464 50mg
Description: ABX464 50mg (One capsule of ABX464 50 mg + One capsule of placebo) once daily for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464 100mg
Description: ABX464 100mg (two capsules of ABX464 50 mg) once daily for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules of placebo once daily for 16 weeks
Study: NCT00638027

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matched tablets bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: memantine
Description: 10 mg bid
Study: NCT05227911

Intervention type: PROCEDURE
Intervention: Abdominal Surgery
Description: Abdominal surgery (laparotomy or laparoscopy) ,which includes proper inspection of the abdominal cavity.
Study: NCT02519738

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Nitrate
Description: Silver nitrate to be applied 3 times weekly for a period of 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kenalog (Triamcinolone)
Description: Triamcinolone will be applied as an ointment to the granulation tissue site three times daily for a total of three weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Washcloth Abrasion
Description: Gentle wash and abrasion with washcloth done once daily for a total of 3 weeks.
Study: NCT00144911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate/Salmeterol Combination Product
Study: NCT02303041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib
Description: Administered orally at starting dose of 80 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib
Description: Administered orally at starting dose of 80 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonidegib
Description: Administered orally at starting dose of 200 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonidegib
Description: Administered orally at starting dose of 200 mg/day
Study: NCT00553306

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies
Study: NCT02032095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB-0998
Study: NCT03441932

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fiberoptic endoscopic evaluation of swallowing (FEES)
Description: Subjets within the two groups will after than have FEES with videotaping of pharyngeal phase after giving subjects a standardised food consisting of thin Puree.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fiberoptic endoscopic evaluation of swallowing (FEES)
Description: Subjets within the two groups will after than have FEES with videotaping of pharyngeal phase after giving subjects a standardised food consisting of thin Puree.
Study: NCT00671918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphoseek
Description: Breast Cancer: Intradermal admin of Lymphoseek: Inject 0.2-0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site OR periareolar administration of Lymphoseek: Inject 0.2-.04 mL in multiple divided doses at the margin of the areola OR subareolar administration of Lymphoseek: Inject 0.2-0.4 in multiple divided injections or a single injection in subareolar area as a subcutaneous injection OR peritumor administration of Lymphoseek: Inject 2.0-4.0 mL in multiple divided injections, intraparenchemally surrounding the tumor or biopsy cavity. For melanoma pts intradermal administration of Lymphoseek: Inject 0.2-0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site.
Study: NCT04536532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC121120 tablets
Description: single-Dose Study: Each dose of HEC121120 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study/Patients with chronic hepatitis B:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HEC121120 placebo tablets
Description: single-Dose Study: Each dose of HEC121120 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study/Patients with chronic hepatitis B:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: entecavir tablets
Description: Patients with chronic hepatitis B：Administered Entecavir orally once daily for consecutive 28 days in fasted state

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: entecavir placebo tablets
Description: Patients with chronic hepatitis B：Administered Entecavir placebo orally once daily for consecutive 28 days in fasted state
Study: NCT02878486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jawbone Up
Description: Jawbone Up is a wrist wore water resistant activity monitor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Education
Description: A study team member will discuss benefits of changing sitting habits and ways to make changes to personal habits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Education
Description: A study team member will discuss benefits of changing sitting habits and ways to make changes to personal habits.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActivPAL
Description: Devices measures postural changes over time. Participants will wear device for 7 days. The device measures time sitting, standing, and posture changes (i.e. sit-to-stand).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ActivPAL
Description: Devices measures postural changes over time. Participants will wear device for 7 days. The device measures time sitting, standing, and posture changes (i.e. sit-to-stand).
Study: NCT04428112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Building Better Caregivers Workshop
Description: Workshops consist of small group or about 20-25 persons. Two peer co-facilitators (caregiver themselves) will guide workshop activities. Participants will receive a workshop booklet. Each week, participants will log on at least 2-3 times for a total time of approximately two hours. Participants do not require real time attendance at pre-determined times.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Participants will receive two brief 15-30 minutes phone calls by study staff, and will receive a handbook on dementia and caregiver resources while they wait for the workshop.
Study: NCT04320121

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nelutri™
Description: Nelutri™ 2,000 mg/day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Placebo 2,000 mg/day for 12 weeks
Study: NCT00892996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Metoclopramide 10 mg and dexamethasone 5 mg intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone 5 mg
Description: Ondansetron 8 mg and dexamethasone 5 mg IV
Study: NCT01051219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: 50 milligrams to be taken orally, daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Losartan
Description: 50 milligrams to be taken orally, daily
Study: NCT05095545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV5080
Description: Hard gelatin capsules with a white body

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV5080
Description: Hard gelatin capsules with a white body

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hard gelatin capsules with a white body
Study: NCT02689050

Intervention type: DEVICE
Intervention: Needle based confocal laser endomicroscopy (nCLE)
Description: During the fine needle aspiration of a suspected and a non-suspected lymph node we will obtain needle based CLE (nCLE) images within the lymph node. Fine needle aspirations will be obtained after the optical biopsy measurements. We will compare the results of the optical biopsy with the cytology results, or to histology in case an additional surgery is indicated.
Study: NCT02603718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation treatment